U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Cannabis Use Disorder

; .

Author Information and Affiliations

Last Update: July 11, 2022.

Continuing Education Activity

Cannabis use can cause intoxication, withdrawal, and biopsychosocial issues. This activity describes the evaluation and management of cannabis use disorder and highlights the role of the interprofessional team in improving care for patients with this condition.


  • Summarize the epidemiology of cannabis use.
  • Review the presentation of a patient with cannabis intoxication.
  • Review the diagnostic criteria for cannabis use disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders.
  • Explain the importance of enhancing care coordination amongst the interprofessional team to optimize care for patients affected by cannabis use disorder.
Access free multiple choice questions on this topic.


Cannabis is considered by the Food and Drug Administration as a Schedule I drug. (Other examples of Schedule I drugs include heroin and peyote.) It has no accepted medical purpose at the federal level and has a high potential for abuse. Most authorities disagree with this designation. Commonly prescribed drugs like opiates and stimulants are Schedule II drugs, meaning they have a high risk of abuse but are medically useful.[1] Benzodiazepines are Schedule IV substances, meaning they have a low potential for abuse and dependence. Despite federal regulations in the latter half of the 20th century, marijuana is still one the most commonly used drug in the United States.[2] The most common users are teenagers and adolescents, and usage tends to decline as these groups age into adulthood due to careers, marriage, cohabitation, and parenthood.[3][4]

Nevertheless, cannabis use has increased with the state-directed legislature turning the tide against federal regulation. State legalization of marijuana has increased cultivation demand, selective breeding for more potent strains, and competition in the marijuana dispensary industry. Expanding the use and legislation for the legalization of marijuana are propagated by potential health benefits and the absence of health concerns that are not well substantiated.

Cannabis abuse is a term describing the continued use of cannabis despite impairment in psychological, physical, or social functioning. It is an outdated medical definition formerly used in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), which divided substance use from substance dependence. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5) has revised the terms of cannabis use disorder defined by nine pathological patterns classified under impaired control, social impairment, risky behavior, or physiological adaptation. This activity will focus on cannabis misuse and related components – states of intoxication and withdrawal and cannabis use disorder.


Cannabis use varies based on demographics. Research shows college students and young adults most commonly use cannabis to socially conform (42%), experiment (29%), and for enjoyment (24%).[5] Twelve percent primarily use the agent to manage stress or relax, consistent with other studies associating its use for depression, anxiety, social anxiety, and post-traumatic stress disorder.[5][6][7][8][9]

During pregnancy, mothers who reported using marijuana say they did so primarily to manage depression, anxiety, and stress (63%), pain (60%), nausea or vomiting (48%), and for recreational purposes (39%).[10]

Biologically speaking, impaired inhibition can predispose individuals to substance use disorders. However, healthcare professionals are unsure if this is true for marijuana.[11]


Nearly four percent of the global population was using cannabis in 2015.[12] Amongst teenagers, eight percent in the US and 16% in Europe report use. Nine percent of all users experience addiction, of which nearly a fifth began to use in adolescence.[1] There is limited evidence for cannabis use among older patients. However, its consumption may be increasing as legal permission for its medical use may justify its use among former non-users. In the medical profession, first-year psychiatry residents are more likely to have Cannabis Use Disorder and seek out experiences to be disinhibited; these individuals also have a history of sedative use and anxiety.[13]

During pregnancy, four percent of mothers admit to using drugs, most commonly with cannabis.[10] A retrospective cohort study of more than 12 million pregnant women revealed nearly a tripling of cannabis abuse or dependence from 1999 through 2003 and a significant association for perinatal complications.[14] Thirty-five percent of mothers who have used marijuana have done so during pregnancy, and 18% used it while breastfeeding.[10] 

As consumption increases among adults, so does the unintended consequence of exposure to children. Between 2005 and 2009, 985 unintentional exposures to children (median age of 1.7 years) were reported. States legalizing marijuana have had a 20-fold increase in calls to poison centers and admissions to critical care units for its exposure.[15]

Overall, the trend for using cannabis is increasing over time for most, if not all demographics.


Researchers know that prolonged and heavy cannabis use can alter brain circuitry. However, the specific pathophysiological mechanisms are yet unclear. In terms of addiction, tetrahydrocannabinol (THC) is the primary molecule responsible for the reinforcing properties of marijuana.[16][17][18] Interestingly, despite the striatal dopamine system typically being involved with substances of abuse such as alcohol and opioids, meta-analysis reveals insufficient evidence at this time to support such a conclusion for cannabis. And also that dopamine receptors may not be involved.[19]

At a symptomatic level, heavy use modifies conscious experience by altering the brain’s network for self-awareness. By reducing anxiety and impairing memory, it also affects motivation and personal experience.[20] At a molecular level, the story is more complex.

The botanical provides over 500 different active chemical compounds, which interact with numerous molecular targets, thereby modulating the transmission of endocannabinoids, gamma-aminobutyric acid, glutamate, and serotonin. Psychoactive effects are primarily derived from tetrahydrocannabinol (THC) which binds cannabinoid receptors (CB)1 and CB2.[21] CB1 receptors are located throughout the central nervous system (CNS), lungs, liver, and kidneys. CB2 receptors predominate within the immune hematopoietic cells.[21] Binding these receptors modulates G-protein-coupled inhibition of cyclic adenosine monophosphate, thereby influencing pain, mood, appetite, nausea, and sexual activity.[21] CNS effects also appear to be mediated by glial cells, particularly microglia and astrocytes. In vitro studies show microglial to produce greater endocannabinoids than neurons, and astrocytes may play a role in signaling by regulating endocannabinoid turnover.[22][23]Thus an influence of the neuropil, not just the neurons, may better describe the CNS changes mediated by cannabis.


Unlike synthetic substances and alcohol, cannabis is a more complex drug. Consumption or inhalation of the botanical exposes the user to hundreds of compounds, including cannabinoids (e.g., THC and cannabidiol) and non-cannabinoids (e.g., terpenes and flavonoids), many of which are bioactive compounds.[21] Compared to isolated pharmaceutical derivatives (e.g., dronabinol and cannabidiol), the sheer complexity of the plant makes a comparison between the two difficult. It is important to establish that what is currently known about marijuana is actually derived from studies of a single active constituent, tetrahydrocannabinol, and less so from the plant itself. This problem is primarily due to its Federal status as a schedule I substance and thus prohibition from federal research funds for its study.

Absorption, Distribution, and Metabolism

THC, the principal psychoactive and addictive component is most commonly smoked. It is rapidly absorbed by the lungs and distributed systemically via perfusion. The rapid influence on the brain contributes to its pleasure and abuse potential.[24] Oral ingestion typically follows a more gradual course and delays its peak blood concentration. It is extensively bound to lipoproteins with only 3% in the free state.[25][26] Metabolism through the liver can produce over 80 metabolites of delta-9-THC, with the most common pathway involving allylic hydroxylation at the 11-position followed by oxidation to a carboxy derivative.[27] Conjugation occurs with some metabolites, but it is not a major step.[27] Bioavailability varies greatly amongst and between individuals depending on their smoking topography, such as number, duration, and spacing of puffs, hold time, and inhalation volume.[28] It remains in the body for extended periods due to its lipophilic properties, allowing it to accumulate and slowly release from adipose tissue, along with its further processing via the enterohepatic circulation, which produces active metabolites as well.[27] 

Chronic daily smokers can produce detectable levels of THC and its metabolites one month after their last intake.[29] It is suggested that its lipophilic metabolites can form conjugates, allowing for greater stability, thereby prolonging its metabolism, and thus half-life, so that release from adipose tissue is the rate-limiting step of THC.[30][31][32] This high lipophilicity explains why withdrawal is a slow onset.

It is worth noting that the pharmacokinetics of THC is further complicated with multiple factors such as its physical/chemical form, route of administration, genetics, and concurrent consumption of alcohol.[27]

History and Physical

Upon evaluation, the patient history should investigate substance use, mental health, family history for substance use and mental health disorder, medical history, medications, substance use amongst social circles (particularly in adolescents), and environmental stressors.

The individual's mental status is a critical part of the exam and can point at the phase of cannabis use. Intoxication can include euphoria, anxiety, uncontrollable laughter, increased appetite, inattentiveness, forgetfulness, restlessness, tachycardia, conjunctival injection, and dry mouth. And less commonly may include delusions, hallucinations, and derealization. Prolonged continuous use or withdrawal typically causes a depressed mood characterized by apathy, lack of motivation, irritability, loss of interest in typical activities, difficulty concentrating, and isolation. (Side note: Cognition can quickly be assessed by testing three-word recall, asking multi-step math problems, or recalling details from a brief fictional story as demonstrated on the St. Louis University Mental Status Exam.) This depressed mood can also include the differential persistent depressive disorder and major depressive disorder. Substance use and a mood or anxiety disorder are not necessarily mutually exclusive and frequently co-occur.  Even suicidality and homicidal tendency can result from dysregulated mood, a recent stressor, or substance use. Differentiation requires an understanding of the intensity and temporality of the symptoms; persistent symptoms during periods of sobriety can indicate a comorbid primary psychiatric disorder.

Classifying cannabis use in the US is dictated by the DSM-5. Generally, it can be understood as the acute and chronic effects. The acute phase includes intoxication and withdrawal states, along with secondary complications - delirium, psychosis, anxiety, and insomnia. Chronic regular use can be characterized by disordered behavior.

Pending on the setting (i.e., emergency department, office visit, or rehabilitation program), different effects of cannabis may be of focus. The diagnostic criteria of the varying effects of cannabis are listed below, as defined by the DSM-5.    

Cannabis Intoxication

  1. Recent use of cannabis        
  2. Clinically significant problematic behavioral or psychological changes (e.g., impaired motor coordination, euphoria, anxiety, a sensation of slowed time, impaired judgment, social withdrawal) that developed during, or shortly after, cannabis use        
  3. At least two of the following signs, developing within 2 hours of cannabis use: conjunctival injection, increased appetite, dry mouth, tachycardia.        
  4. Symptoms not due to a general medical condition and are not better accounted for by another mental disorder.
  5. Specify if perceptual disturbances are present: hallucinations with intact reality testing or auditory, visual, or tactile illusions occur in the absence of delirium.   

Cannabis Withdrawal

  1. This accompanies cessation of cannabis use that has been heavy and prolonged (i.e., usually daily or almost daily use over a period of at least a few months). Three or more of the following signs and symptoms develop within approximately 1 week after cessation of heavy, prolonged use:            
    1. Irritability, anger, or aggression           
    2. Nervousness or anxiety            
    3. Sleep difficulty (i.e., insomnia, disturbing dreams)            
    4. Decreased appetite or weight loss            
    5. Restlessness            
    6. Depressed mood        
  2. At least one of the following physical symptoms causing significant discomfort: abdominal pain, shakiness/tremors, sweating, fever, chills, or a headache.        
  3. The signs or symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.        
  4. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication or withdrawal from another substance.

It should be noted that evidence suggests that withdrawal only occurs in a subset of patients.[33] Symptoms usually begin within the first 24 hours, peak by day 3, and can last for up to 2 weeks.[33] Increased use and more recent use can predict the severity of withdrawal.[34][35]

Cannabis Intoxication Delirium

This diagnosis relies on the definition of delirium and is appropriate when the following two symptoms predominate in someone who has taken cannabis:            

  1. Disturbance in attention (i.e., reduced ability to direct focus, sustain, and shift attention) and awareness (reduced orientation to the environment)
  2. An additional disturbance in cognition (i.e., memory deficit, disorientation, language, visuospatial ability, or perception).

Cannabis-induced Psychotic Disorder  

  1. Presence of delusions or hallucinations.            
  2. Evidence from the history, physical examination, or laboratory findings of either one of the following:           
    1. The symptoms in the first criterion developed during or soon after cannabis intoxication or withdrawal.            
    2. The disturbance is not accounted for by a psychotic disorder that is not substance-induced.
    3. Evidence that the symptoms are accounted for by a psychotic disorder that is not substance induced might include the following:            
      1. The symptoms precede the onset of substance use (or medication use).      
      2. The symptoms persist for a substantial period (e.g., about a month) after the cessation of acute withdrawal or severe intoxication or are substantially more than what would be expected, given the type or amount of the substance used or the duration of use.      
      3. Other evidence suggests the existence of an independent non–substance-induced psychotic disorder (e.g., a history of recurrent non–substance-related episodes).      
      4. The disturbance does not occur exclusively during delirium.    
      5. The disturbance causes clinically significant distress or impairment in social, occupational, or other areas of functioning. 

Cannabis-induced Anxiety Disorder  

  1. Panic attacks or anxiety predominate in the clinical picture.            
  2. Evidence from the history, physical examination, or laboratory findings of either of the following:                
    1. The symptoms in the first criterion developed during or soon after substance intoxication or withdrawal.                
    2. The disturbance is not better accounted for by an anxiety disorder that is not substance-induced. Evidence that the symptoms are better accounted for by an anxiety disorder that is not substance induced might include the following:                    
    3. The symptoms precede the onset of substance use.                    
    4. The symptoms persist for a substantial period (e.g., about a month) after cessation of acute withdrawal or severe intoxication or are substantially more than expected given the type or amount of the substance used or the duration of use.                    
    5. Other evidence suggests the existence of an independent non–substance-induced anxiety disorder (e.g., a history of recurrent non–substance-related episodes).                
    6. The disturbance does not occur exclusively during delirium.               
    7. The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.      

Cannabis-induced Sleep Disorder

  1. A prominent and severe disturbance in sleep.            
  2. There is evidence from the history, physical examination, or laboratory findings of both of the following:            
    1. The symptoms in the first criterion developed during or soon after cannabis intoxication or after withdrawal from or exposure to it.          
    2. The disturbance is not better explained by a sleep disorder that is not substance/medication-induced. Such evidence of an independent sleep disorder could include that:               
    3. The symptoms precede the onset of cannabis use.          
    4. The symptoms persist for a substantial period (i.e., about a month) after the cessation of acute withdrawal or severe intoxication.         
    5. There is other evidence suggesting the existence of an independent non-substance/medication-induced sleep disorder (i.e., a history of recurrent non-substance/medication-related episodes).           
    6. The disturbance does not occur exclusively during delirium.                
    7. The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.

The Chronic Effects: Cannabis Use Disorder

Cannabis abuse and dependence were combined in the DSM-5 into a single entity capturing the behavioral disorder that can occur with chronic cannabis use and named Cannabis Use Disorder; it is defined as:        

  1. A problematic pattern of cannabis use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:       
  2. Cannabis is often taken in larger amounts or over a longer period than was intended.        
  3. There is a persistent desire or unsuccessful efforts to cut down or control cannabis use.        
  4. A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects.        
  5. Craving, or a strong desire or urge to use cannabis.        
  6. Recurrent cannabis use results in failure to fulfill role obligations at work, school, or home.        
  7. Continued cannabis use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis.        
  8. Important social, occupational, or recreational activities are given up or reduced because of cannabis use.
  9. Recurrent cannabis use in situations in which it is physically hazardous.        
  10. Cannabis use continues despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis. 
  11. Tolerance, as defined by either: (1) a need for markedly increased cannabis to achieve intoxication or desired effect or (2) a markedly diminished effect with continued use of the same amount of the substance.       
  12. Withdrawal, as manifested by either (1) the characteristic withdrawal syndrome for cannabis or (2) cannabis is taken to relieve or avoid withdrawal symptoms.

It has the following specifiers:    

In early remission - After full criteria for cannabis use disorder were previously met, none of the criteria for cannabis use disorder has been met for at least three months but less than 12 months (with an exception provided for craving).    

In sustained remission - After full criteria for cannabis use disorder were previously met, none of the criteria for cannabis use disorder has been met at any time during 12 months or longer (with an exception provided for craving).

Severity is graded as either Mild, Moderate, or Severe, pending if 2 or 3, 4 or 5, or 6+ of the above criteria are present.


Laboratory testing of urine, blood, saliva, or hair can be useful to detect cannabis use, but results should be considered along with a clinical rationale. Assays typically rely on the detection of the most common active metabolite, delta-9-tetrahydrocannibinolic acid. It has been studied thoroughly, and this abundant acid metabolite has become an established urinary marker of cannabis consumption in forensic, clinical, and environmental analyses.[27] A positive result can indicate usage but not necessarily a substance use disorder or intoxication, and a negative result does not rule it out. It is possible to quantify tolerance by comparing the reported intake of cannabis to blood levels. Heavy or chronic cannabis smokers will take longer to clear THC compared to sporadic or one-time users.

Also, other tests to rule out additional conditions may be of benefit. These include head imaging or laboratory testing of heavy metals, infection and immunological markers, electrolyte disturbances, or hormones.

Treatment / Management

The aim should be to improve the individual's overall function, which is multiphasic and multifactorial. Supportive treatment may be provided during detoxification; enabling access to psychiatric services allows addressing underlying disorders; psychological counseling can modify behavior, develop healthier coping skills in the face of stressors, and enlighten them regarding their temperament.

As cannabis strains become more potent and accessible, the risk will increase for the frequency and severity of serious adverse reactions. For individuals with marked intoxication or withdrawal or cannabis use disorder, the goal should be to stop the drug altogether. As opposed to abrupt cessation, a gradual decrease is likely to decrease the discomfort of the withdrawal and prevent relapse. Cannabis intoxication most often does not require medical management and will self-resolve. Supportive management such as a calm, non-stimulating environment helps patients. Symptomatic treatment can be considered for specific symptoms such as alpha-2-adrenergic agonists or beta-blockers for tachycardia, benzodiazepines for panic attacks, off-label use of first-generation antihistamines for anxiety and restlessness, and neuroleptics for psychosis. It is important to monitor psychological symptoms, which may be features of the withdrawal or part of the patient’s primary psychiatric illness - which may not have been previously identified.

Pharmacologic detoxification is still under investigation. A systematic review indicates most studies are preliminary and cannot statistically support clinical rationale as they are small sizes, inconsistent, and have a risk of attrition bias.[36]

No medication has FDA approval to treat cannabis use disorder. Tetrahydrocannabinol does show some potential in treatment, but more information is needed to demonstrate the validity and inform on the dose, duration, formulation, and adjunct therapies.[36] Gabapentin and N-acetylcysteine are also used but have unclear benefits.[36] Another component of cannabis, cannabidiol, holds promise by modulating the serotonergic, glutamatergic, and endocannabinoid systems.[37]

Differential Diagnosis

Cannabis intoxication, cannabis withdrawal, and cannabis use disorder: the differential may include intoxication syndromes from other substances. These may include amphetamine or cocaine intoxication, withdrawal from benzodiazepines or hypnotics, atrial tachycardia, an anxiety disorder, and panic attacks. A thorough medical history, psychiatric history, substance use history, family psychiatric and medical history, medication review, toxicology screen, and blood alcohol level are needed. Endogenous psychiatric disorders such as generalized anxiety disorder or panic disorder or a primary psychotic disorder such as schizophrenia spectrum disorder will typically demonstrate symptomology before and long after cessation of cannabis. Collateral sources, typically from family members, long-standing friends, or other providers, can help.

Toxicity and Adverse Effect Management

Side effects for short-term use of cannabis include impaired short-term memory, which can affect learning, impaired motor coordination in activities such as driving, and an increase in high-risk sexual behaviors.[1] Also, judgment is impaired on tasks measuring the quality of decision-making and executive planning.[38]

Children aged less than twelve are a separate concern. Their exposure typically occurs via unintentional consumption of edibles meaning the dosage of THC taken in is not considered. This has led to increased presentations to the emergency department, often for central nervous system depression such as lethargy and somnolence, and rarely for respiratory insufficiency.[39]


The likelihood of continuing cannabis abuse can vary from person to person. Impulsive individuals are more likely to experiment with substances, including cannabis.[40] Using cannabis for experimentation is associated with less use and fewer problems.[5] Factors such as enjoyment, habit, activity enhancement, and altered perception or perspectives are associated with heavier use and more problems.[5] Those more avoidant of punishment, boredom, or unpleasant events are less likely to discontinue use and are at risk for abuse.[40] Also, those experiencing withdrawal or who are avoidant of stressful situations can perpetuate usage.[40]


Heavy or chronic users are more likely to report a decreased sense of life satisfaction and achievement compared to the general population.[1] Additionally, effects can impair neuropsychiatric, physical, and social domains. These include addiction, altered brain development, cognitive impairment, poor educational outcome, increased likelihood of dropping out of school, and lower IQ among frequent users during adolescence.[1] In addition to acute users, also chronic users demonstrate cognitive and psychomotor driving impairments.[41][42][43][44] Females may be more likely to demonstrate deficits in attentional inhibition (i.e., ignoring irrelevant features in a situation.)[45] Those with the tendency for chronic psychotic disorders are at increased risk of "unmasking the illness" with prolonged use.[1] THC levels measured in hair amongst chronic heavy marijuana-only users were predictive of delusions, hallucinations, and organic brain dysfunction.[46] Discontinuation of cannabis did not resolve these symptoms even after three months, indicating organic neurological dysfunction.[46]

Also at risk is the respiratory system, as the byproducts of combustion and heated smoke can result in chronic bronchitis with inhaled use.[1] Chronic use may also affect fertility in both sexes may.[47]

The risk is not only restricted to the user. Extensive evidence of perinatal cannabis exposure reveals the future child to have a risk for a broad array of cognitive impairments, including intelligence, attention, activity, restraint, visual-motor coordination, processing speed, visual memory, and interhemispheric transfer of information as late as adolescence.[48][49][50][51] There is evidence, albeit inconclusive, for potential risk for preterm delivery, low birth weight, and stillbirth; wherever the truth may lie, it should not be considered a harmless substance.[52][53][54][55][14][56][14]


Consultation for cannabis use disorder includes involving behavioral health for substance use disorder and psychopathology management. Neurology or pain management for chronic pain interventions and sleep professionals for insomnia if needed. All specialties, including emergency providers, should also include the primary care provider as they are best suited for long-term monitoring and most accessible for early interventions.

Deterrence and Patient Education

With increasing misinformation about cannabis being safe with no risks, it is important to bring evidence to the discussion. Providers need to educate patients, especially those under the age of 21, who are at a higher risk for long-term, potentially irreversible, cognitive impairments. Pregnant patients should be counseled, whether they admit to usage or not, on the potential impact of cannabis on the fetus. Adults should be informed that cannabis and its paraphernalia should be kept in a locked and hidden location to prevent pediatric intoxication if they desire to use it. Despite the legalization of medical marijuana in many states, employers can still enforce their company policies and terminate workers who present to work intoxicated or test positive for cannabis.

Pearls and Other Issues

Providers across all specialties need to familiarize themselves with the effects of cannabis use. It is increasingly becoming ubiquitous in our society. The evidence supporting the use of marijuana for specific conditions is limited and most often derived from pharmaceutical preparations of isolated THC. Researchers struggle to gain funding for these studies given that it is a schedule I controlled substance with the Food and Drug Administration. Providers should know that providing permission to access medical marijuana for a given symptom does not restrict that patient to its limited usage. The dispensary’s employees can influence the strain, dosing, formulation, and indications used based on an opinion. Also, it should be stressed that continuous and/or heavy use of cannabis can increase the risk of intoxication or withdrawal, requiring medical attention, and long-term complications, which may be irreversible.

Despite its more benign nature compared to an opiate, benzodiazepine, and alcohol use, it is still a substance with a potential for ill health effects and marked impairment on social and occupational functioning. With the expansion of evidence-based uses, it is important to separate the abuse of marijuana from use with thorough history taking. Differences in state regulations governing medical indications for cannabis should be considered. And providers should not forget that medical marijuana is a not product of the tightly regulated and scientifically back pharmaceutical industry - it is a product produced by growing operations without similar oversight and indicated for conditions mostly not based on rigorous medical or scientific evidence required for products they prescribe, as opposed to a permitted use.

Enhancing Healthcare Team Outcomes

Deterring patients from substance use is often best supported by a team effort with the goal of relieving the underlying cause. A non-judgemental approach to understanding the reasons for use is best. Among children, cannabis use can indicate coping with home or school stressors. Counseling, particularly cognitive behavioral therapy and multidimensional family therapy, should be provided at school, home, or an outpatient clinic to improve behavioral issues in both environments.[57] [Level 1b] Assessment by psychiatry for mental health disorders is important. Among adults, a similar strategy may be utilized with counseling and psychiatry. There is a longitudinal relationship between reductions in cannabis use and improvements in anxiety, depression, sleep quality, but not the quality of life.[58] [Level 3]

Peer Network Counseling-txt (PNC-txt), a 4-week, automated text-delivered cannabis treatment that focuses on close peer relations, was able to decrease usage and relationship problems.[59] [Level 1b] Also, intensive outpatient programs for substance use disorders can be beneficial. For chronic pain, pain management or neurology can be involved. For insomnia, sleep studies are useful. Providers should know that a patient with a history of substance use disorder is more likely to misuse controlled substances, and tools for monitoring controlled prescriptions should be utilized if available.

In summary, an interprofessional team approach to managing marijuana use disorder is necessary. This team will including clinicians, mid-level practitioners, nurses, pharmacists, social workers, and other mental health professionals who can collaboratively address the issue, oversee prescribed medical marijuana, and openly share patient data to ensure the best possible outcomes. [Level 5]

Review Questions


Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014 Jun 05;370(23):2219-27. [PMC free article: PMC4827335] [PubMed: 24897085]
Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012 Feb;87(2):172-86. [PMC free article: PMC3538401] [PubMed: 22305029]
Chen K, Kandel DB. Predictors of cessation of marijuana use: an event history analysis. Drug Alcohol Depend. 1998 Apr 01;50(2):109-21. [PubMed: 9649962]
Duncan GJ, Wilkerson B, England P. Cleaning up their act: the effects of marriage and cohabitation on licit and illicit drug use. Demography. 2006 Nov;43(4):691-710. [PubMed: 17236542]
Lee CM, Neighbors C, Woods BA. Marijuana motives: young adults' reasons for using marijuana. Addict Behav. 2007 Jul;32(7):1384-94. [PMC free article: PMC2723942] [PubMed: 17097817]
Moitra E, Christopher PP, Anderson BJ, Stein MD. Coping-motivated marijuana use correlates with DSM-5 cannabis use disorder and psychological distress among emerging adults. Psychol Addict Behav. 2015 Sep;29(3):627-32. [PMC free article: PMC4586302] [PubMed: 25915689]
Bonn-Miller MO, Vujanovic AA, Zvolensky MJ. Emotional dysregulation: association with coping-oriented marijuana use motives among current marijuana users. Subst Use Misuse. 2008;43(11):1653-65. [PubMed: 18752166]
Buckner JD, Bonn-Miller MO, Zvolensky MJ, Schmidt NB. Marijuana use motives and social anxiety among marijuana-using young adults. Addict Behav. 2007 Oct;32(10):2238-52. [PMC free article: PMC1986747] [PubMed: 17478056]
Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007 Aug;20(4):577-86. [PubMed: 17721963]
Lipari RN, Hedden SL, Hughes A. The CBHSQ Report. Substance Abuse and Mental Health Services Administration (US); Rockville (MD): Sep 4, 2014. Substance Use and Mental Health Estimates from the 2013 National Survey on Drug Use and Health: Overview of Findings; pp. 1–10. [PubMed: 27656739]
Wang GS. Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization. J Med Toxicol. 2017 Mar;13(1):99-105. [PMC free article: PMC5330955] [PubMed: 27139708]
Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, Giovino GA, West R, Hall W, Griffiths P, Ali R, Gowing L, Marsden J, Ferrari AJ, Grebely J, Farrell M, Degenhardt L. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018 Oct;113(10):1905-1926. [PubMed: 29749059]
Fond G, Bourbon A, Micoulaud-Franchi JA, Auquier P, Boyer L, Lançon C. Psychiatry: A discipline at specific risk of mental health issues and addictive behavior? Results from the national BOURBON study. J Affect Disord. 2018 Oct 01;238:534-538. [PubMed: 29936392]
Petrangelo A, Czuzoj-Shulman N, Balayla J, Abenhaim HA. Cannabis Abuse or Dependence During Pregnancy: A Population-Based Cohort Study on 12 Million Births. J Obstet Gynaecol Can. 2019 May;41(5):623-630. [PubMed: 30448107]
Wang GS, Roosevelt G, Le Lait MC, Martinez EM, Bucher-Bartelson B, Bronstein AC, Heard K. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann Emerg Med. 2014 Jun;63(6):684-9. [PubMed: 24507243]
Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996 Nov;91(11):1585-614. [PubMed: 8972919]
De Luca MA, Di Chiara G, Cadoni C, Lecca D, Orsolini L, Papanti D, Corkery J, Schifano F. Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update. CNS Neurol Disord Drug Targets. 2017;16(5):598-609. [PubMed: 28412916]
Russo EB, Marcu J. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Adv Pharmacol. 2017;80:67-134. [PubMed: 28826544]
Kamp F, Proebstl L, Penzel N, Adorjan K, Ilankovic A, Pogarell O, Koller G, Soyka M, Falkai P, Koutsouleris N, Kambeitz J. Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies. Neuropsychopharmacology. 2019 Mar;44(4):660-667. [PMC free article: PMC6372711] [PubMed: 30188512]
Pujol J, Blanco-Hinojo L, Batalla A, López-Solà M, Harrison BJ, Soriano-Mas C, Crippa JA, Fagundo AB, Deus J, de la Torre R, Nogué S, Farré M, Torrens M, Martín-Santos R. Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J Psychiatr Res. 2014 Apr;51:68-78. [PubMed: 24411594]
Papaseit E, Pérez-Mañá C, Pérez-Acevedo AP, Hladun O, Torres-Moreno MC, Muga R, Torrens M, Farré M. Cannabinoids: from pot to lab. Int J Med Sci. 2018;15(12):1286-1295. [PMC free article: PMC6158663] [PubMed: 30275754]
Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003 Feb 15;23(4):1398-405. [PMC free article: PMC6742252] [PubMed: 12598628]
Melis M, Frau R, Kalivas PW, Spencer S, Chioma V, Zamberletti E, Rubino T, Parolaro D. New vistas on cannabis use disorder. Neuropharmacology. 2017 Sep 15;124:62-72. [PMC free article: PMC5865400] [PubMed: 28373077]
Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992 Sep-Oct;16(5):276-82. [PubMed: 1338215]
Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980 Sep;28(3):409-16. [PubMed: 6250760]
Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992 Jul-Aug;16(4):228-35. [PubMed: 1323733]
Dinis-Oliveira RJ. Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity. Drug Metab Rev. 2016;48(1):80-7. [PubMed: 26828228]
Perez-Reyes M. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. NIDA Res Monogr. 1990;99:42-62. [PubMed: 2176276]
Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem. 2013 Mar;59(3):519-26. [PMC free article: PMC3717350] [PubMed: 23449702]
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-60. [PubMed: 12648025]
Johansson E, Halldin MM. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol. 1989 Jul-Aug;13(4):218-23. [PubMed: 2550702]
Johansson E, Norén K, Sjövall J, Halldin MM. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr. 1989 Jan;3(1):35-8. [PubMed: 2539872]
Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37. [PMC free article: PMC5414724] [PubMed: 28490916]
Preuss UW, Watzke AB, Zimmermann J, Wong JW, Schmidt CO. Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend. 2010 Jan 15;106(2-3):133-41. [PubMed: 19783382]
Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004 Nov;161(11):1967-77. [PubMed: 15514394]
Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014;12(12):CD008940. [PMC free article: PMC4297244] [PubMed: 25515775]
Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335. [PMC free article: PMC6998871] [PubMed: 29789034]
Grant JE, Chamberlain SR, Schreiber L, Odlaug BL. Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend. 2012 Feb 01;121(1-2):159-62. [PMC free article: PMC3242860] [PubMed: 21920674]
Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr. 2013 Jul;167(7):630-3. [PubMed: 23712626]
Prince van Leeuwen A, Creemers HE, Verhulst FC, Ormel J, Huizink AC. Are adolescents gambling with cannabis use? A longitudinal study of impulsivity measures and adolescent substance use: the TRAILS study. J Stud Alcohol Drugs. 2011 Jan;72(1):70-8. [PubMed: 21138713]
Bondallaz P, Favrat B, Chtioui H, Fornari E, Maeder P, Giroud C. Cannabis and its effects on driving skills. Forensic Sci Int. 2016 Nov;268:92-102. [PubMed: 27701009]
Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, Jeffery WK, Walls HC, van Leeuwen CJ, Ramaekers JG. Medicinal Δ(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction. 2012 Oct;107(10):1837-44. [PubMed: 22553980]
Bosker WM, Theunissen EL, Conen S, Kuypers KP, Jeffery WK, Walls HC, Kauert GF, Toennes SW, Moeller MR, Ramaekers JG. A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid. Psychopharmacology (Berl). 2012 Oct;223(4):439-46. [PMC free article: PMC3456923] [PubMed: 22581391]
Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N. Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biol Psychiatry. 2016 Apr 01;79(7):557-67. [PubMed: 26858214]
Albertella L, Le Pelley ME, Copeland J. Frequent cannabis use is associated with reduced negative priming among females. Exp Clin Psychopharmacol. 2016 Oct;24(5):313-319. [PubMed: 27337025]
Nestoros JN, Vakonaki E, Tzatzarakis MN, Alegakis A, Skondras MD, Tsatsakis AM. Long lasting effects of chronic heavy cannabis abuse. Am J Addict. 2017 Jun;26(4):335-342. [PubMed: 28314070]
Bari M, Battista N, Pirazzi V, Maccarrone M. The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci (Landmark Ed). 2011 Jan 01;16(2):498-516. [PubMed: 21196184]
Day NL, Richardson GA, Goldschmidt L, Robles N, Taylor PM, Stoffer DS, Cornelius MD, Geva D. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol. 1994 Mar-Apr;16(2):169-75. [PubMed: 8052191]
Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000 May-Jun;22(3):325-36. [PubMed: 10840176]
Willford JA, Chandler LS, Goldschmidt L, Day NL. Effects of prenatal tobacco, alcohol and marijuana exposure on processing speed, visual-motor coordination, and interhemispheric transfer. Neurotoxicol Teratol. 2010 Nov-Dec;32(6):580-8. [PMC free article: PMC2975798] [PubMed: 20600845]
Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol. 2003 Jul-Aug;25(4):427-36. [PubMed: 12798960]
Hayatbakhsh MR, Flenady VJ, Gibbons KS, Kingsbury AM, Hurrion E, Mamun AA, Najman JM. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res. 2012 Feb;71(2):215-9. [PubMed: 22258135]
Saurel-Cubizolles MJ, Prunet C, Blondel B. Cannabis use during pregnancy in France in 2010. BJOG. 2014 Jul;121(8):971-7. [PubMed: 24621183]
Prunet C, Delnord M, Saurel-Cubizolles MJ, Goffinet F, Blondel B. Risk factors of preterm birth in France in 2010 and changes since 1995: Results from the French National Perinatal Surveys. J Gynecol Obstet Hum Reprod. 2017 Jan;46(1):19-28. [PubMed: 28403953]
van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N., National Birth Defects Prevention Study. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend. 2010 Jun 01;109(1-3):243-7. [PubMed: 20171023]
Varner MW, Silver RM, Rowland Hogue CJ, Willinger M, Parker CB, Thorsten VR, Goldenberg RL, Saade GR, Dudley DJ, Coustan D, Stoll B, Bukowski R, Koch MA, Conway D, Pinar H, Reddy UM., Eunice Kennedy Shriver National Institute of Child Health and Human Development Stillbirth Collaborative Research Network. Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet Gynecol. 2014 Jan;123(1):113-125. [PMC free article: PMC3931517] [PubMed: 24463671]
van der Pol TM, Hendriks V, Rigter H, Cohn MD, Doreleijers TAH, van Domburgh L, Vermeiren RRJM. Multidimensional family therapy in adolescents with a cannabis use disorder: long-term effects on delinquency in a randomized controlled trial. Child Adolesc Psychiatry Ment Health. 2018;12:44. [PMC free article: PMC6098634] [PubMed: 30140308]
Hser YI, Mooney LJ, Huang D, Zhu Y, Tomko RL, McClure E, Chou CP, Gray KM. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017 Oct;81:53-58. [PMC free article: PMC5607644] [PubMed: 28847455]
Mason MJ, Zaharakis NM, Moore M, Brown A, Garcia C, Seibers A, Stephens C. Who responds best to text-delivered cannabis use disorder treatment? A randomized clinical trial with young adults. Psychol Addict Behav. 2018 Nov;32(7):699-709. [PubMed: 30265057]
Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013 Aug;170(8):834-51. [PMC free article: PMC3767415] [PubMed: 23903334]

Disclosure: Jason Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Raman Marwaha declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK538131PMID: 30844158


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...